title: O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.
abstract: Factor VIII (FVIII) is an important cofactor in the blood coagulation cascade. A deficiency or dysfunction of FVIII causes hemophilia A, a life-threatening bleeding disorder. FVIII circulates in plasma as a heterodimer comprising 6 domains (heavy chain, A1-A2-B and light chain, A3-C1-C2). Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein. Neutralizing antibodies to epitopes in the lipid binding region of FVIII are commonly identified in patients' plasma. In this report, we investigated the effect of O-phospho-L-serine (OPLS), which binds to the lipid binding region, on the immunogenicity of B domain deleted recombinant factor VIII (BDDrFVIII). Sandwich enzyme-linked immunosorbent assay (ELISA) studies showed that OPLS specifically bind to the lipid binding region, localized in the C2 domain of the coagulation factor. Size exclusion chromatography and fluorescence anisotropy studies showed that OPLS interfered with the aggregation of BDDrFVIII. Immunogenicity of free- vs BDDrFVIII-OPLS complex was evaluated in a murine model of hemophilia A. Animals administered subcutaneous (sc) injections of BDDrFVIII-OPLS had lower neutralizing titers compared with animals treated with BDDrFVIII alone. Based on these studies, we hypothesize that specific molecular interactions between OPLS and BDDrFVIII may improve the stability and reduce the immunogenicity of BDDrFVIII formulations.
authors: Department of Molecular & Cellular Biophysics and Biochemistry, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors: Razvan D
authors: RD
authors: Miclea
authors: Vivek S
authors: VS
authors: Purohit
authors: Sathy V
authors: SV
authors: Balu-Iyer
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood / Q000276:immunology; D001665:Binding Sites; D003029:Coagulants / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004355:Drug Stability; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology; D005079:Excipients / Q000737:chemistry*; D005169:Factor VIII / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood* / Q000276:immunology / Q000628:therapy; D006801:Humans; D066298:In Vitro Techniques; D008081:Liposomes; D051379:Mice; D018345:Mice, Knockout; D009500:Neutralization Tests; D010314:Partial Thromboplastin Time; D010768:Phosphoserine / Q000737:chemistry*; D011485:Protein Binding; D017510:Protein Folding
chemical_list: D000911:Antibodies, Monoclonal; D003029:Coagulants; D000939:Epitopes; D005079:Excipients; D008081:Liposomes; D010768:Phosphoserine; C078147:F8 protein, human; D005169:Factor VIII